Widecells Group plc (LON:WDC) CEO Joao Andrade & Non-executive director Dr Marilyn Orcharton, talks to DirectorsTalk about what’s behind CellPlan, what the receipt of the licence means for Widecells, a new route to market and their hopes for the stem cell industry.
WideCells Group PLC is building an integrated stem cell services company, focused on making stem cell treatments accessible and affordable. The Directors believe that the use of cord blood stem cells for transplant will drive one of the next important phases in medicine and is therefore developing market leading products in complementary, strategic areas which are designed to take advantage of substantial market opportunities in one of the fastest growing segments in the healthcare industry.
With this in mind, it has created three divisions:
· CellPlan: the world’s first stem cell healthcare insurance plan with financial cover for medical treatment, travel and accommodation expenses and concierge service to manage the treatment process
· WideCells: the Institute of Stem Cell Technology has been established and is based in the University of Manchester Innovation Center to focus on stem cell research and regenerative medicine. WideCells also has international cryogenics divisions specialising in stem cell storage.